Envarsus XR (Tacrolimus) Patent Expiration, LOE Window & CMS Spending
Envarsus XR (Tacrolimus) by Veloxis: FDA Orange Book LOE 2028-08-30, 14 AB generics, $64.0M 2024 CMS Part D & Medicaid spend, and 18 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Veloxis |
| FDA Application & Pathway | N206406 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2028-08-30 |
| Orange Book Patents (*PED Extensions) | 10 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 14 |
| 2024 CMS Total Public Spend | $64.0M |
| 2024 Medicare Part D Spend | $16.9M |
| 2024 Medicaid Spend | $47.2M |
| Reported Wholesale Price Change (CA SB 17) | 18 WAC filings (max 20.0% 2-yr change) |